Samsung Bioepis has joined Sandoz in being unable to offer its biosimilar etanercept product in the US until 2029 after a New Jersey district court entered a final judgment and order of permanent injunction against the firm pertaining to two US patents covering Amgen’s Enbrel (etanercept) anti-TNF original.
The Korean-based joint venture between Samsung BioLogics and Biogen has held US Food and Drug Administration approval for its Eticovo (etanercept-ykro) biosimilar since April 2019 but has been unable to launch due to intellectual property hurdles